Oncotarget

Research Papers:

Discriminating patients with early-stage breast cancer from benign lesions by detection of oxidative DNA damage biomarker in urine

Cheng Guo _, Xiaofen Li, Minfeng Ye, Fei Xu, Jiekai Yu, Cong Xie, Xiaoji Cao, Mengzhe Guo, Ying Yuan and Shu Zheng

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:53100-53109. https://doi.org/10.18632/oncotarget.17831

Metrics: PDF 1012 views  |   HTML 1448 views  |   ?  


Abstract

Cheng Guo1,*, Xiaofen Li1,*, Minfeng Ye1,2,*, Fei Xu1, Jiekai Yu1, Cong Xie3, Xiaoji Cao3, Mengzhe Guo4, Ying Yuan5 and Shu Zheng1

1Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China

2Department of Gastrointestinal Surgery, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, China

3College of Chemical Engineering, Zhejiang University of Technology, Hangzhou, Zhejiang 310014, China

4Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, Jiangsu 221004, China

5Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China

*These authors have contributed equally to this work

Correspondence to:

Cheng Guo, email: cheng_guo@zju.edu.cn

Mengzhe Guo, email: guomengzhe@xzhmu.edu.cn

Shu Zheng, email: zhengshu@zju.edu.cn

Keywords: breast cancer, benign lesion, biomarker, urine, mass spectrometry

Received: January 11, 2017     Accepted: April 12, 2017     Published: May 12, 2017

ABSTRACT

Breast cancer is one of the most commonly diagnosed and death-related cancers in women worldwide. Mammography is routinely used for screening and invasive examinations such as painful tissue biopsies were recommended for patients with abnormal screening outcomes. However, a considerable proportion of these cases turn out to be benign lesions. Thus, novel non-invasive approach for discriminating breast cancer from benign lesions is desirable. Herein, we applied a high-throughput ultra performance liquid chromatography-electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS) analysis to determine the oxidative DNA damage biomarker, 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) in urine samples from 60 patients with early-stage breast cancer (stage I, II), 51 patients with benign breast diseases and 73 healthy volunteers. We demonstrated that the concentration of urinary 8-oxodG in patients with early-stage breast cancer was significantly higher not only than that in healthy controls, but also than that in patients with benign breast diseases, whereas no significant difference of urinary 8-oxodG level was observed between benign breast diseases group and healthy control group. Moreover, there was significant difference between early-stage breast cancer group and non-cancerous group which consisted of benign breast diseases patients and healthy controls. Besides, logistic regression analysis and receiver operator characteristic (ROC) curve analysis were also performed. Our findings indicate that the marked increase of 8-oxodG in urine may serve as a potential biomarker for the risk estimation, early screening and detection of breast cancer, particularly for discriminating early-stage breast cancer from benign lesions.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17831